Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Gunilla Høyer-Hansen
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Procedures
Living Beings
Disorders
Anatomy
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
29
Danø, Keld
23
Rønne, E
16
Brünner, Nils
14
Ploug, Michael
12
Behrendt, Niels
9
Lund, Leif
8
Stephens, Ross
7
Rømer, John
7
Ullum, Henrik
7
Nielsen, Hans Jørgen
7
Ostrowski, Sisse
7
Christensen, Ib Jarle
6
Gårdsvoll, Henrik
6
Pass, Jesper
6
Pedersen, Bente Klarlund
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Gunilla Høyer-Hansen (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Almasi Charlotte Elberling; Høyer-Hansen Gunilla; Christensen Ib Jarle; Pappot Helle
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(10):755-61.
-
2009: Henic Emir; Noskova Vera; Høyer-Hansen Gunilla; Hansson Stefan; Casslén Bertil
Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):214-22.
-
2008: Lund Ida K; Jögi Annika; Rønø Birgitte; Rasch Morten G; Lund Leif R; Almholt Kasper; Gårdsvoll Henrik; Behrendt Niels; Rømer John; Høyer-Hansen Gunilla
Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo.
The Journal of biological chemistry 2008;283(47):32506-15.
-
2008: Rasch Morten G; Pass Jesper; Illemann Martin; Høyer-Hansen Gunilla; Lund Ida K
Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Journal of immunological methods 2008;339(1):55-65.
-
2008: Henic Emir; Borgfeldt Christer; Christensen Ib Jarle; Casslén Bertil; Høyer-Hansen Gunilla
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5785-93.
-
2007: Jögi A; Pass J; Høyer-Hansen G; Lund L R; Nielsen B S; Danø K; Rømer J
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice.
Journal of thrombosis and haemostasis : JTH 2007;5(9):1936-44.
-
2007: Madsen Daniel H; Engelholm Lars H; Ingvarsen Signe; Hillig Thore; Wagenaar-Miller Rebecca A; Kjøller Lars; Gårdsvoll Henrik; Høyer-Hansen Gunilla; Holmbeck Kenn; Bugge Thomas H; Behrendt Niels
Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation.
The Journal of biological chemistry 2007;282(37):27037-45.
-
2007: Pass Jesper; Jögi Annika; Lund Ida K; Rønø Birgitte; Rasch Morten G; Gårdsvoll Henrik; Lund Leif R; Ploug Michael; Rømer John; Danø Keld; Høyer-Hansen Gunilla
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Thrombosis and haemostasis 2007;97(6):1013-22.
-
2007: Ostrowski S R; Shulman C E; Peshu N; Staalsøe T; Høyer-Hansen G; Pedersen B K; Marsh K; Ullum H
Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.
Parasite immunology 2007;29(1):37-46.
-
2007: Høyer-Hansen Gunilla; Lund Ida Katrine
Urokinase receptor variants in tissue and body fluids.
Advances in clinical chemistry 2007;44():65-102.
-
2006: Ostrowski S R; Katzenstein T L; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen B K; Ullum H
Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Scandinavian journal of immunology 2006;63(6):478-86.
-
2006: Piironen Timo; Haese Alexander; Huland Hartwig; Steuber Thomas; Christensen Ib Jarle; Brünner Nils; Danø Keld; Høyer-Hansen Gunilla; Lilja Hans
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Clinical chemistry 2006;52(5):838-44.
-
2006: Henic Emir; Sixt Michael; Hansson Stefan; Høyer-Hansen Gunilla; Casslén Bertil
EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Gynecologic oncology 2006;101(1):28-39.
-
2006: Andersen Ase B; Law Ian; Ostrowski Sisse R; Lebech Anne Mette; Høyer-Hansen Gunilla; Højgaard Liselotte; Gerstoft Jan; Ullum Henrik; Kjaer Andreas
Self-reported fatigue common among optimally treated HIV patients: no correlation with cerebral FDG-PET scanning abnormalities.
Neuroimmunomodulation 2006;13(2):69-75.
-
2005: Almasi Charlotte Elberling; Høyer-Hansen Gunilla; Christensen Ib Jarle; Danø Keld; Pappot Helle
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Lung cancer (Amsterdam, Netherlands) 2005;48(3):349-55.
-
2005: Larsen M B; Stephens R W; Brünner N; Nielsen H J; Engelholm L H; Christensen I J; Stetler-Stevenson W G; Høyer-Hansen G
Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
Scandinavian journal of immunology 2005;61(5):449-60.
-
2005: Ostrowski Sisse Rye; Piironen Timo; Høyer-Hansen Gunilla; Gerstoft Jan; Pedersen Bente Klarlund; Ullum Henrik
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2005;39(1):23-31.
-
2005: Ostrowski S R; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen B K; Ullum H
Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Scandinavian journal of immunology 2005;61(4):347-56.
-
2005: Danø Keld; Behrendt Niels; Høyer-Hansen Gunilla; Johnsen Morten; Lund Leif R; Ploug Michael; Rømer John
Plasminogen activation and cancer.
Thrombosis and haemostasis 2005;93(4):676-81.
-
2005: Ostrowski Sisse R; Ullum Henrik; Goka Bamenla Q; Høyer-Hansen Gunilla; Obeng-Adjei George; Pedersen Bente K; Akanmori Bartholomew D; Kurtzhals Jørgen A L
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
The Journal of infectious diseases 2005;191(8):1331-41.
-
2005: Usher Pernille Autzen; Thomsen Ole Frøkjaer; Iversen Peter; Johnsen Morten; Brünner Nils; Høyer-Hansen Gunilla; Andreasen Peter; Danø Keld; Nielsen Boye Schnack
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
International journal of cancer. Journal international du cancer 2005;113(6):870-80.
-
2005: Ostrowski S R; Plomgaard P; Fischer C P; Steensberg A S; Møller K; Høyer-Hansen G; Pedersen B K; Ullum H
Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells.
Scandinavian journal of immunology 2005;61(2):197-206.
-
2004: Piironen Timo; Laursen Birgitte; Pass Jesper; List Karin; Gårdsvoll Henrik; Ploug Michael; Danø Keld; Høyer-Hansen Gunilla
Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Clinical chemistry 2004;50(11):2059-68.
-
2004: Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson S R; Casslén B
Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Molecular human reproduction 2004;10(9):655-63.
-
2004: Illemann Martin; Hansen Ulla; Nielsen Hans Jørgen; Andreasen Peter A; Høyer-Hansen Gunilla; Lund Leif R; Danø Keld; Nielsen Boye Schnack
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.
American journal of clinical pathology 2004;122(2):256-65.
-
2004: Begum Farah Diba; Høgdall Claus K; Kjaer Susanne K; Christensen Lise; Blaakaer Jan; Bock Johannes E; Glud Eva; Høyer-Hansen Gunilla; Ring-Larsen Helmer; Høgdall Estrid V S
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Anticancer research 2004;24(3b):1981-5.
-
2003: Offersen Birgitte Vrou; Nielsen Boye Schnack; Høyer-Hansen Gunilla; Rank Fritz; Hamilton-Dutoit Stephen; Overgaard Jens; Andreasen Peter A
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.
The American journal of pathology 2003;163(5):1887-99.
-
2003: Pass J; Gårdsvoll H; Lund L R; Danø K; Høyer-Hansen G
Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response.
Scandinavian journal of immunology 2003;58(3):298-305.
-
2002: Riisbro Rikke; Christensen Ib J; Piironen Timo; Greenall Michael; Larsen Berthe; Stephens Ross W; Han Cheng; Høyer-Hansen Gunilla; Smith Kenneth; Brünner Nils; Harris Adrian L
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1132-41.
-
2001: Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
The Biochemical journal 2001;358(Pt 3):673-9.
-
2001: Solberg H; Ploug M; Høyer-Hansen G; Nielsen B S; Lund L R
The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2001;49(2):237-46.
-
2000: Hedberg K K; Stauff C; Høyer-Hansen G; Rønne E; Griffith O H
High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells.
Experimental cell research 2000;257(1):67-81.
-
2000: Høyer-Hansen G; Hamers M J; Pedersen A N; Nielsen H J; Brünner N; Danø K; Stephens R W
Loss of ELISA specificity due to biotinylation of monoclonal antibodies.
Journal of immunological methods 2000;235(1-2):91-9.
-
2000: Gårdsvoll H; Solberg H; Dano K; Høyer-Hansen G
Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization.
Journal of immunological methods 2000;234(1-2):107-16.
-
1999: Pedersen A N; Brünner N; Høyer-Hansen G; Hamer P; Jarosz D; Larsen B; Nielsen H J; Stephens R W
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
Clinical chemistry 1999;45(8 Pt 1):1206-13.
-
1999: Holten-Andersen M N; Murphy G; Nielsen H J; Pedersen A N; Christensen I J; Høyer-Hansen G; Brünner N; Stephens R W
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
British journal of cancer 1999;80(3-4):495-503.
-
1999: List K; Høyer-Hansen G; Rønne E; Danø K; Behrendt N
Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology.
Journal of immunological methods 1999;222(1-2):125-33.
-
1998: Wahlberg K; Høyer-Hansen G; Casslén B
Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Cancer research 1998;58(15):3294-8.
-
1997: Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner K T
The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
FEBS letters 1997;420(1):79-85.
-
1997: Stephens R W; Pedersen A N; Nielsen H J; Hamers M J; Høyer-Hansen G; Rønne E; Dybkjaer E; Danø K; Brünner N
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
Clinical chemistry 1997;43(10):1868-76.
-
1997: Pappot H; Høyer-Hansen G; Rønne E; Hansen H H; Brünner N; Danø K; Grøndahl-Hansen J
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33(6):867-72.
-
1997: Pedersen A N; Høyer-Hansen G; Brünner N; Clark G M; Larsen B; Poulsen H S; Danø K; Stephens R W
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Journal of immunological methods 1997;203(1):55-65.
-
1997: Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
European journal of biochemistry / FEBS 1997;243(1-2):21-6.
-
1996: Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Clinical & experimental metastasis 1996;14(3):297-307.
-
1995: Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne C K; Clark G M; Danø K; Grøndahl-Hansen J
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Breast cancer research and treatment 1995;33(3):199-207.
-
1995: Rønne E; Pappot H; Grøndahl-Hansen J; Høyer-Hansen G; Plesner T; Hansen N E; Danø K
The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 1995;89(3):576-81.
-
1994: Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
International journal of cancer. Journal international du cancer 1994;58(6):877-81.
-
1994: Rømer J; Pyke C; Lund L R; Eriksen J; Kristensen P; Rønne E; Høyer-Hansen G; Danø K; Brünner N
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
International journal of cancer. Journal international du cancer 1994;57(4):553-60.
-
1994: Bastholm L; Nielsen M H; De Mey J; Danø K; Brünner N; Høyer-Hansen G; Rønne E; Elling F
Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane.
Biotechnic & histochemistry : official publication of the Biological Stain Commission 1994;69(2):61-7.
-
1994: Plesner T; Ploug M; Ellis V; Rønne E; Høyer-Hansen G; Wittrup M; Pedersen T L; Tscherning T; Danø K; Hansen N E
The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils.
Blood 1994;83(3):808-15.
-
1994: Pyke C; Ralfkiaer E; Rønne E; Høyer-Hansen G; Kirkeby L; Danø K
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Histopathology 1994;24(2):131-8.
-
1994: Conforti G; Dominguez-Jimenez C; Rønne E; Høyer-Hansen G; Dejana E
Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer.
Blood 1994;83(4):994-1005.
-
1994: Rønne E; Behrendt N; Ploug M; Nielsen H J; Wöllisch E; Weidle U; Danø K; Høyer-Hansen G
Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Journal of immunological methods 1994;167(1-2):91-101.
-
1993: Pedersen N; Schmitt M; Rønne E; Nicoletti M I; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
The Journal of clinical investigation 1993;92(5):2160-7.
-
1993: Myöhänen H T; Stephens R W; Hedman K; Tapiovaara H; Rønne E; Høyer-Hansen G; Danø K; Vaheri A
Distribution and lateral mobility of the urokinase-receptor complex at the cell surface.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1993;41(9):1291-301.
-
1993: Ploug M; Kjalke M; Rønne E; Weidle U; Høyer-Hansen G; Danø K
Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.
The Journal of biological chemistry 1993;268(23):17539-46.
-
1993: Pyke C; Graem N; Ralfkiaer E; Rønne E; Høyer-Hansen G; Brünner N; Danø K
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Cancer research 1993;53(8):1911-5.
-
1993: Behrendt N; Ploug M; Rønne E; Høyer-Hansen G; Danø K
Cellular receptor for urokinase-type plasminogen activator: protein structure.
Methods in enzymology 1993;223():207-22.
-
1992: Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund L R; Ellis V; Danø K
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
The Journal of biological chemistry 1992;267(25):18224-9.
-
1992: Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun T C; Appella E; Danø K; Blasi F
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
The Journal of biological chemistry 1992;267(13):9129-33.
-
1992: Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1992;205(2):451-8.
-
1992: Ploug M; Plesner T; Rønne E; Ellis V; Høyer-Hansen G; Hansen N E; Danø K
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Blood 1992;79(6):1447-55.
-
1991: Rønne E; Behrendt N; Ellis V; Ploug M; Danø K; Høyer-Hansen G
Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.
FEBS letters 1991;288(1-2):233-6.
Sign-in to see more
